the same year it was approved by EMA. In 2011 Merck & Co. entered clinical trials with vibegron with the indication for OAB. and phase III clinical trials began in 2018. In 2018 solabegron, which has been acquired by Velicept Therapeutics, Inc., started phase I and phase II clinical trials in men and women, respectively, for the indication of OAB. See also Beta-adrenergic agonist Beta2-adrenergic agonist References